ZURICH (Reuters) – Swiss drug ingredients maker Bachem has begun round-the-clock production of Propofol as worldwide demand for the medicine that helps sedate mechanically ventilated patients has skyrocketed during the COVID-19 pandemic.
In addition to expanding Propofol production at its facility in Vionnaz in southern Switzerland, Bachem said on Monday that it is also investing about 1 million Swiss francs ($1.03 million) in additional equipment to guarantee supply capacity.
(Reporting by John Miller; editing by Thomas Seythal)
